Urokinase-type plasminogen activator soluble receptor (suPAR) assay in clinical routine: evaluation one year after its introduction in the high automation corelab of the A. Gemelli hospital

Clin Chem Lab Med. 2022 Oct 27;61(2):e33-e35. doi: 10.1515/cclm-2022-0686. Print 2023 Jan 27.

Authors

Francesca Sarlo¹, Andrea Urbani^{1

2}, Silvia Baroni^{1

2

3}

Affiliations

¹ UOC di Chimica Biochimica e Biologia Molecolare Clinica, Fondazione Policlinico Universitario A. Gemelli I.R.C.C.S., Rome, Italy.
² Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy.
³ UOS Corelab Biochimica Clinica Urgenze, Fondazione Policlinico Universitario A. Gemelli I.R.C.C.S., Rome, Italy.

PMID: 36283064
DOI: 10.1515/cclm-2022-0686

No abstract available

Keywords: SARS-CoV-2; automation systems; soluble urokinase plasminogen activator receptor; suPAR.

Publication types

Letter

MeSH terms

Automation
Biomarkers
Hospitals
Humans
Receptors, Urokinase Plasminogen Activator*
Signal Transduction
Urokinase-Type Plasminogen Activator*

Substances

Receptors, Urokinase Plasminogen Activator
Urokinase-Type Plasminogen Activator
Biomarkers